Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines

Inflammation Research

Volumn 54, Issue 7, 2005, Pages 273-280

  Herman, S ^a   Zurgil, N ^a   Deutsch, M ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Apoptosis; Leukocytes; Methotrexate (MTX); Reactive oxygen species (ROS); Rheumatoid arthritis (RA)

Indexed keywords

ACETYLCYSTEINE; LIPOCORTIN 5; METHOTREXATE; NITROBLUE TETRAZOLIUM; REACTIVE OXYGEN METABOLITE; TRYPAN BLUE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SIZE; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE; MONOCYTE; NITROBLUE TETRAZOLIUM TEST; T LYMPHOCYTE ACTIVATION;

ACETYLCYSTEINE; ANNEXIN A5; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LEUKOCYTES; METHOTREXATE; MONOCYTES; OXIDATIVE STRESS; PROPIDIUM; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; U937 CELLS;

EID: 23944510494     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-005-1355-8     Document Type: Article

References (70)

1. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
2. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
3. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76: 907-12.
4. Sperling RI, Benincaso AI, Austen KF, Anderson RJ, Coblyn JS, Weinblatt ME. Effects of methotrexate therapy on 5-lipoxygenase pathway metabolism of arachidonic acid in rheumatoid arthritis. Arthritis Rheum 1990; 33: 173.
5. Fairbanks LD, Ruckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis. Biochem J 1999; 342: 143-52.
6. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
7. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295-300.
8. Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000; 59: 311-4.
9. Schuerwegh AJ, van Offel JF, Bridts CH, Stevens WJ, De Clerck LS. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1793-9.
10. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
11. Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T. Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998; 41: 1-9.
12. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: a possible model for predicting methotrexate therapy for rheumatoid arthritis patients. Cell Struct Funct 2003; 28: 113-22.
13. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-66.
14. Xiao GF, Lu Q, Yang XD. Gene expression in apoptotic process of acute myeloid leukemia cell line U937 induced by methotrexate. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002; 10: 104-7. Chinese.
15. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in non-active patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol Invest 2004; 33: 1-12.
16. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770.
17. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929-31.
18. Goel R, Khanduja KL. Oxidative stress-induced apoptosis - an overview. Baculovirus 1998; 75: 1338-45.
19. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994; 15: 7-10.
20. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84: 131-41.
21. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 1999; 57: 231-45.
22. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-7.
23. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 1996; 21: 83-6.
24. Matsuda M, Masutani H, Nakamura H, Miyajima S, Yamauchi A, Yonehara S et al. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 1991; 147: 3837-41.
25. Schulze-Osthoff K, Krammer PH, Droge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 1994; 13: 4587-96.
26. Hirose K, Longo DL, Oppenheim JJ, Matsushima K. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J 1993; 7: 361-8.
27. Chang DJ, Ringold GM, Heller RA. Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-alpha is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun 1992; 188: 538-46.
28. Bustamante J, Slater AF, Orrenius S. Antioxidant inhibition of thymocyte apoptosis by dihydrolipoic acid. Free Radic Biol Med 1995; 19: 339-47.
29. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK et al. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 2000; 47: 35-44.
30. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003; 138: 501-11.
31. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 2003; 45: 7-13.
32. Gressier B, Lebegue S, Brunet C, Luyckx M, Dine T, Cazin M et al. Pro-oxidant properties of methotrexate: evaluation and prevention by an anti-oxidant drug. Pharmazie 1994; 49: 679-81.
33. Babiak RM, Campello AP, Carnieri EG, Oliveira MB. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 1998; 16: 283-93.
34. Gao F, Horie T. A synthetic analog of prostaglandin E(1) prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats. Life Sci 2002; 71: 1091-9.
35. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 1999; 84: 668-77.
36. Visconti A, Minervini F, Lucivero G, Gambatesa V. Cytotoxic and immunotoxic effects of Fusarium mycotoxins using a rapid colorimetric bioassay. Mycopathologia 1991; 113: 181-6.
37. Deutsch M, Zurgil N, Kaufman M, Berke G. Fluorescence polarization as an early measure of T-lymphocyte stimulation. In: Kearse KP, editor. Methods in Molecular Biology. vol. 134. T Cell Protocols: Development and Activation. Totowa NJ: Humana Press, 2000: 221-42
38. Deutsch M, Tirosh R, Kaufman M, Zurgil N, Weinreb A. Fluorescence polarization as a functional parameter in monitoring living cells: theory and practice. J Fluorescence 2002; 12: 25-44.
39. Cercek L, Cercek B. Application of the phenomenon of changes in the structuredness of cytoplasmic matrix (SCM) in the diagnosis of malignant disorders: a review. Eur J Cancer 1977; 13: 903-15.
40. Shapiro HM. Practical Flow Cytometry. Third edition. New York: Alan R Liss Inc, 1995.
41. Zurgil N, Schiffer Z, Shafran Y, Kaufman M, Deutsch M. Fluorescein fluorescence hyperpolarization as an early kinetic measure of the apoptotic process. Biochem Biophys Res Commun 2000; 268: 155-63.
42. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001; 97: 3544-51.
43. Moller B, Kukoc-Zivojnov N, Okamgba S, Kessler U, Pucetti E, Ottmann OG et al. Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatol Int 2002; 22: 60-7.
44. Monjanel-Mouterde S, Lafforgue P, Blanc A, Catalin J, Aquaviva PC, Durand A. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis. J Rheumatol 1998; 25: 1276-81.
45. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998; 25: 238-42.
46. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28: 721-30.
47. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97: 2027-37.
48. Salazar-Fontana LI, Sanz E, Merida I, Zea A, Sanchez-Atrio A, Villa L et al. Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis. Clin Immunol 2001; 99: 253-65.
49. Cooper BA. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996; 124: 73.
50. Goronzy JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, Weyand CM. Dominant clonotypes in the repertoire of peripheral CD4+ cells in rheumatoid arthritis. J Clin Invest 1994; 94: 2068-76.
51. Waase I, Kayser C, Carlson PJ, Goronzy JJ, Weyand CM. Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum 1996; 39: 904-13.
52. Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999; 11: 210-7.
53. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6.
54. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997; 40: 984-5.
55. Aarvak T, Natvig JB. Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res 2001; 3: 13-7.
56. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18: 7719-30.
57. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999; 274: 2225-33.
58. Jianrong L, Christopher AB, Sufang Y, Young-Myeong K, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem 1999; 274: 17325-33.
59. Takahashi A, Masuda A, Sun M, Centonze VE, Herman B. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm). Brain Res Bull 2004; 62: 497-504.
60. Barragan M, Campas C, Bellosillo B, Gil J. Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 1865-70.
61. Chen J, Gu LJ, Ying DM. Low dose methotrexate combined with GM-CSF induced differentiation of U937 cells. Zhonghua Xue Ye Xue Za Zhi 2003; 24: 430-2. Chinese.
62. Rezk BM, Haenen GR, van der Vijgh WJ, Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett 2003; 555: 601-5.
63. Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, Rogers E. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003; 14: 32-42.
64. Campise M, Bamonti F, Novembrino C, Ippolito S, Tarantino A, Cornelli U et al. Oxidative stress in kidney transplant patients. Transplantation 2003; 76: 1474-8.
65. Chern CL, Huang RF, Chen YH, Cheng JT, Liu TZ. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother 2001; 55: 434-42.
66. Tjiattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, Shea TB. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 2004; 3: 71-6.
67. Lesko SA, Tso POP, Yang SU, Zheng RL. In: McBrien DCH, Slater TF, editors. Free Radicals, Lipid Peroxidation and Cancer. London: Academic Press, 1982: 401-14.
68. Diomede L, Colotta F, Piovani B, Re F, Modest EJ, Salmona M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac- glycero-3-phosphocholine. A possible basis for its selective action. Int J Cancer 1993; 53: 124-30.
69. Burden RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18: 775-94.
70. Ren JG, Zheng RL, Shi YM, Gong B, Li JF. Apoptosis, redifferentiation and arresting proliferation simultaneously triggered by oxidative stress in human hepatoma cells. Cell Biol Int 1998; 22: 41-9.